Prolonged treatments with antiresorptive agents and PTH have different effects on bone strength and the degree of mineralization in old estrogen-deficient osteoporotic rats.
about
Expression of muscarinic acetylcholine receptors M3 and M5 in osteoporosis.The Beneficial Effects of Bisphosphonate-enoxacin on Cortical Bone Mass and Strength in Ovariectomized Rats.A targeted approach for evaluating preclinical activity of botanical extracts for support of bone health.Effect of sequential treatments with alendronate, parathyroid hormone (1-34) and raloxifene on cortical bone mass and strength in ovariectomized rats.Higher doses of bisphosphonates further improve bone mass, architecture, and strength but not the tissue material properties in aged ratsAging and estrogen status: a possible endothelium-dependent vascular coupling mechanism in bone remodeling.Strontium ranelate improves bone microarchitecture in osteoporosis.The effects of parathyroid hormone applied at different regimes on the trochanteric region of the femur in ovariectomized rat model of osteoporosisDifferential maintenance of cortical and cancellous bone strength following discontinuation of bone-active agentsEffects of sequential osteoporosis treatments on trabecular bone in adult rats with low bone massChanges in intracortical microporosities induced by pharmaceutical treatment of osteoporosis as detected by high resolution micro-CT.Parathyroid hormone regulates the distribution and osteoclastogenic potential of hematopoietic progenitors in the bone marrowAlterations in the osteocyte lacunar-canalicular microenvironment due to estrogen deficiency.Impact of maternal prenatal stress on growth of the offspringThe combination therapy with zoledronic Acid and propranolol improves the trabecular microarchitecture and mechanical property in an rat model of postmenopausal osteoporosis.Bone Matrix Composition Following PTH Treatment is Not Dependent on Sclerostin Status.
P2860
Q33728414-E466D715-69C0-4FC8-84DD-E3123D3452A9Q33770077-6C89AB0E-B24B-48EF-9813-07B41969B372Q34125733-895A99E9-A386-4D98-8B1C-36D6AF5FF856Q34149279-10D833E0-9960-44D7-8CAF-ED7F8995C776Q34411999-96F0D8C3-860E-4270-AF72-B0431E6F68D0Q34489715-AAB4EB97-BBDD-4063-8E2F-8448FF2AD67CQ34612210-9906F537-12DE-4AB6-9A85-C015C10C0D79Q34986470-9354A30F-98AA-43A7-8AE1-9AC8C8EF80CFQ35229871-7171D56D-7B94-468A-854A-506C86237A20Q35384673-6CF76EFA-04CE-4037-A67C-8001F97F5DA2Q35754017-B91E1411-1741-4DC5-AB2B-973819EE98C7Q35853991-57CC2885-25C4-466B-A868-ECAA5C4B9E67Q36144039-F9C9303B-1FAE-4ED7-A280-E083C39FFEEDQ37513991-D3032A54-0C38-414B-A053-8A164F583617Q37706415-385D206F-DBD0-4539-902E-E5176C917C17Q51666670-B9C2D6A4-B125-4400-A239-CC6D4646C69A
P2860
Prolonged treatments with antiresorptive agents and PTH have different effects on bone strength and the degree of mineralization in old estrogen-deficient osteoporotic rats.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Prolonged treatments with anti ...... n-deficient osteoporotic rats.
@ast
Prolonged treatments with anti ...... n-deficient osteoporotic rats.
@en
type
label
Prolonged treatments with anti ...... n-deficient osteoporotic rats.
@ast
Prolonged treatments with anti ...... n-deficient osteoporotic rats.
@en
prefLabel
Prolonged treatments with anti ...... n-deficient osteoporotic rats.
@ast
Prolonged treatments with anti ...... n-deficient osteoporotic rats.
@en
P2093
P2860
P356
P1476
Prolonged treatments with anti ...... n-deficient osteoporotic rats.
@en
P2093
Cheryl Busse
Elizabeth A Zimmermann
Nancy E Lane
Robert O Ritchie
Zhiqiang Cheng
P2860
P304
P356
10.1359/JBMR.81005
P577
2009-02-01T00:00:00Z